Study on How Filter Lifespan in Continuous Renal Replacement Therapy Affects New Infection Rates in Critically Ill Adults

What this Trial Is About

Approximately half of the patients in intensive care units ICU experience acute kidney injury AKI, which complicates their treatment. Continuous renal replacement therapy CRRT is commonly used to support kidney function in these critically ill patients, as it allows continuous and controlled fluid removal and is better tolerated than intermittent dialysis. However, the use of CRRT involves intravascular access and artificial circuits that may increase infection risk. This observational trial aims to study factors influencing new infections in critically ill patients receiving CRRT, focusing on the impact of filter lifespan. This study observes critically ill patients undergoing continuous renal replacement therapy without altering their treatment, which is directed by their ICU physicians. There are no specific interventions assigned by the study, as it is purely observational. Researchers will monitor patients from the start of dialysis for up to 28 days or until the end of CRRT, collecting data on infections, filter lifespan, and other clinical events. Participants will be closely evaluated through various assessments during their ICU stay, including tracking new infections such as bloodstream infections, pneumonia, urinary tract infections, and catheter-related infections. Additional data on dialysis downtime, duration of mechanical ventilation, bleeding complications, kidney function recovery, and mortality will be collected up to 90 days after dialysis starts. The trial will analyze these outcomes to better understand infection risks and patient recovery in this vulnerable population.

Filter Lifespan in Continuous Renal Replacement Therapy